Eckert & Ziegler: Major Order for Prostate Implants

Berlin, June 1, 2010 - The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in medical use of radioactivity, has gained over its Belgian subsidiary IBt BEBIG (International Brachytherapy S.A.) a major order in France for the supply of medical devices for prostate cancer treatment.

During the next three years the specialist in radiation therapy will deliver miniature implants, typically used to treat early stage prostate cancer, to specialised hospitals in Angers, Caen, Nice, Strasbourg and Rouen. The multiple million Euro contract contains also the supply of the renowned Institut Curie in Paris, where brachytherapy was born. Presumably more than 1,000 patients will benefit from the low-level radioactive implants.

The commissioning hospitals are part of Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), a consortium of 20 well-known French cancer research centers, in which the state activities in the area of cancer treatment and research are coordinated.

The Eckert & Ziegler Group, with around 520 employees, is one of the world's largest providers of isotope technology components for radiotherapy and nuclear medicine.

The Board of Directors